Johnson & Johnson vs Vanguard High Dividend Yield ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Vanguard High Dividend Yield ETF trades at $158.75 (market cap $100.80B). The key difference: Johnson & Johnson is far larger — about 6.1× Vanguard High Dividend Yield ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard High Dividend Yield ETF for 139 Days on average.
| JNJ | VYM | |
|---|---|---|
Market Cap | $618.09B | $100.80B |
Volume | 6,050,983 | 908,176 |
Sector | Health | — |
52-Week High | $278.43 | $167.03 |
52-Week Low | $186.00 | $137.47 |
Typical Hold Time | 129 Days | 139 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
VYM trades at $158.25, up 0.51% with a bearish technical signal. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $156 and resistance at $159. Recent news highlights VYM's consistent dividend yield of 2.42% but notes competitive pressure from alternatives like SCHD and IDV, which have outperformed recently. The fund's index methodology has faced criticism for holding stocks like Intel and Walgreens through dividend cuts.
Outlook remains cautious due to technical bearishness and competitive headwinds. While VYM offers broad diversification and low costs, investors face risks from its yield-focused strategy potentially including dividend-cut vulnerable stocks. The fund serves income investors but may underperform more dynamic dividend strategies in current market conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →